Marisol Herrera Marmolejo

Author

Also Known As

M. H. Marmolejo, M. Herrera Marmolejo, Marisol Herrera Marmolejo

Publications

522

Citations

H-Index

Concepts

All Affiliations

Marisol Herrera Marmolejo is an author at Bristol-Myers Squibb (Germany) specializing in pharmacotherapy, medicine, and pharmacology.

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	213
2	Pharmacology	2	2	213
3	Diabetes	1	1	62
4	Nephrology	1	1	151
5	Diabetes Complications	1	1	62

Marisol Herrera Marmolejo

Publications

522

Citations

H-Index

Page 1

	Year	Citations
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial Robert R. Henry, Alexander V. Murray, Marisol Herrera Marmolejo, International Journal of Clinical Practice	2012	309
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani, The Lancet HypertensionRenal FunctionRenal DiseaseMedicineKidney Failure	2023	151
Efficacy and safety of triple therapy with dapagliflozin add‐on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes Chantal Mathieu, Marisol Herrera Marmolejo, José Gerardo González‐González, Diabetes Obesity and Metabolism ObesityMetabolic SyndromeDiabetes ManagementCardiovascular DiseaseWeek 52	2016	62

Page 1